Bristol Myers Squibb Launches Phase 2/3 Clinical Trial of PRMT5 Inhibitor BMS-986504 in MTAP-Deficient Metastatic Pancreatic Cancer

▎Armstrong

On July 21, 2025, Bristol-Myers Squibb registered a Phase 2/3 clinical trial, MountainTAP-30, on Clinicaltrials.gov for the PRMT5 inhibitor BMS-986504 in combination with chemotherapy as a first-line treatment for metastatic MTAP-deleted pancreatic cancer.

This Phase 2/3 clinical trial plans to enroll 470 patients with advanced pancreatic cancer and is expected to be completed in May 2029.

At the AACR-NCI-EORTC conference at the end of 2024, Bristol-Myers Squibb announced the Phase 1/2 clinical trial of BMS-986504 for the treatment of MTAP-deficient solid tumors. With a median follow-up time of 5.8 months, 107 patients were evaluable for efficacy, and the ORR was 19.6%. In subgroup analyses across different tumor types, non-small cell lung cancer...The ORR of patients was 30% (6/20)., Pancreatic CancerThe ORR of patients was 10% (3/30).，The ORR for mesothelioma patients was 42.9% (3/7).，CholangiocarcinomaThe ORR of patients was 22% (2/9), and the median response duration for all patients was 4.2 months.

Homozygous deletion of MTAP leads to the accumulation of its substrate, methylthioadenosine (MTA).Accumulation, MTA competes with SAM, the cofactor of PRMT5, to form the PRMT5-MTA complex.

Summary

BMS-986504 is currently in Phase II clinical trials for non-small cell lung cancer, with data expected to be available in 2028. We look forward to its subsequent clinical progress and hope that the PRMT5 target will complete clinical Proof of Concept (POC) as soon as possible.